CCR5 blockade decreased the percentage of MDSCs and inhibited melanoma proliferation, mainly through upregulating suppressor of cytokine signaling 3 (SOCS3) expression, which in turn inhibited the IL-STAT3 pathway (Hawila et al., 2017). The gene discussed is SOCS3; the disease is melanoma.